2024
Durlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis
Nantongo M, Nguyen D, Bethel C, Taracila M, Li Q, Dousa K, Shin E, Kurz S, Nguyen L, Kreiswirth B, Boom W, Plummer M, Bonomo R. Durlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases 2024, 10: 1767-1779. PMID: 38619138, DOI: 10.1021/acsinfecdis.4c00119.Peer-Reviewed Original ResearchConceptsESI-MSElectrospray ionization mass spectrometryIonization mass spectrometryB-lactamase inhibitorsAcyl-enzyme complexMycobacterial cell wall synthesisMolecular dockingMass spectrometryActive siteInhibit BlaCPeptidoglycan transpeptidaseDiazabicyclooctaneSynthesisAntibiotic susceptibility testingCell wall synthesisInhibition kineticsDrug targetsB-lactamaseDurlobactamSusceptibility testingComplexDockingSpectrometryWall synthesisPeptidoglycan synthesis
2022
1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase
Nguyen D, Redmond S, Dousa K, Bethel C, Taracila M, Li Q, Kurz S, Pavelka M, Papp-Wallace K, Holland S, Kreiswirth B, Boom H, Bonomo R. 1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase. Open Forum Infectious Diseases 2022, 9: ofac492.1261. PMCID: PMC9752925, DOI: 10.1093/ofid/ofac492.1261.Peer-Reviewed Original ResearchDrug-resistant tuberculosisB-lactamaseMTB isolatesDifficult-to-treat infectionsB-lactamase inhibitorsFractional inhibitory concentration indexMultidrug-resistant mycobacteriaIn vitro susceptibilityCystic Fibrosis FoundationBroth microdilution methodPG synthasesElectrospray ionization-mass spectrometryCeftriaxone MICsDR-TBSusceptibility testingImipenemMeropenemTB guidelinesCeftriaxoneB-lactamTreatment strategiesClinical studiesLowered MICClavulanateMicrodilution method
2019
1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
Dousa K, Kurz S, Bethel C, Barnes M, Taracilla M, Selvaraju S, Jacobs M, Kreiswirth B, Kasperbauer S, Daley C, Bonomo R. 1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy. Open Forum Infectious Diseases 2019, 6: s503-s503. PMCID: PMC6809419, DOI: 10.1093/ofid/ofz360.1249.Peer-Reviewed Original ResearchB-lactamaseColony-forming unitsIn vitro susceptibility testingB-lactamase inhibitorsTherapeutically achievable concentrationsMab infectionRescue regimenMiddlebrook 7H9 brothVisible bacterial growthSusceptibility testingClinical isolatesImipenemBlaMabTreated patientsRelebactamAvibactamNontuberculous mycobacteriaB-lactamM. abscessusMAB isolatesTest agentsIn vitro inhibitionMAb complexesMAbMIC
2017
Drug Resistance Assays for Mycobacterium tuberculosis
Kurz S, Salfinger M. Drug Resistance Assays for Mycobacterium tuberculosis. 2017, 1359-1365. DOI: 10.1007/978-3-319-47266-9_33.Peer-Reviewed Original ResearchDetection of drug resistanceEpidemic of drug-resistant tuberculosisAgar proportion methodAntimicrobial susceptibility testingDrug-resistant tuberculosisDrug resistance assaysDetection of patientsDrug-resistant Mycobacterium tuberculosis strainsMycobacterium tuberculosis strainsMinimal inhibitory concentrationPharmacodynamic correlationsSusceptibility testingDrug resistanceLiquid medium systemsEffective treatmentTuberculosis strainsScreening testProportion methodGenotyping methodsResistance assaysBacteriological methodsInhibitory concentrationMycobacterium tuberculosisTuberculosisPatients
2011
Are We Ready for Novel Detection Methods to Treat Respiratory Pathogens in Hospital-Acquired Pneumonia?
Endimiani A, Hujer K, Hujer A, Kurz S, Jacobs M, Perlin D, Bonomo R. Are We Ready for Novel Detection Methods to Treat Respiratory Pathogens in Hospital-Acquired Pneumonia? Clinical Infectious Diseases 2011, 52: s373-s383. PMID: 21460299, PMCID: PMC3106236, DOI: 10.1093/cid/cir054.Peer-Reviewed Original ResearchConceptsHospital-acquired pneumoniaGenetic determinants of antimicrobial resistanceDeterminants of antimicrobial resistanceAntimicrobial susceptibility testingAntibiotic-resistant pathogensHospital-acquired bacterial pneumoniaPathogen-directed therapyDifficult treatment challengeCharacterize pathogensResults of cultureSusceptibility testingDiagnosis of pneumoniaEmpirical therapyAntimicrobial resistancePathogensHospital-acquiredPulmonary microbiomeBacterial pneumoniaMolecular diagnosticsPolymerase chain reactionTreatment challengesMolecular testingRespiratory pathogensPneumoniaChain reaction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply